Benlysta: What you need to know

Introduction: Overview of Benlysta and Its Role in Autoimmune Disease Treatment 

Autoimmune diseases develop when the immune system, which normally protects us from infections, mistakenly attacks the body’s own healthy tissues.1 In systemic lupus erythematosus (SLE, or “lupus”), this abnormal response can cause widespread inflammation and damage to multiple organs.2 For many years, treatment has relied on traditional immunosuppressive medications that broadly reduce immune activity. While these drugs can help control disease symptoms, patients often require long-term, high-dose therapy. This can weaken the body’s defences, making patients vulnerable to serious infections and increasing their long-term risk of certain types of cancer. In addition, many of these medications are associated with significant side effects that can limit their use. Thus, targeted biologic therapies aim to interfere with key immune pathways, potentially resulting in fewer side effects. 3 One such therapy, Benlysta (belimumab), is the first and only FDA-approved biologic specifically for autoimmune disorders (SLE and lupus nephritis).4,5 

What Is Benlysta (Belimumab)? 

Benlysta is a fully human monoclonal antibody developed to neutralize B-lymphocyte stimulator (BLyS), a protein critical for the survival of autoreactive B cells. It helps to reduce the disease activity without completely shutting down normal immune function. It is available in intravenous and subcutaneous forms.6 

Approved Indications: Where Benlysta Is Used 

Benlysta (belimumab) is used to treat: 

• Patients aged ≥5 with active, autoantibody-positive SLE who are receiving standard therapy. 
• Patients aged ≥18 with active lupus nephritis who are receiving standard therapy.  

• The subcutaneous formulation is approved for patients aged ≥18 years. 

Limitations of Use: The efficacy of Benlysta has not been evaluated in patients with severe active central nervous system lupus, nor has it been assessed in combination with other biologics. Therefore, its use is not recommended in these scenarios.5 

Mechanism of Action: How Benlysta Works in the Immune System 

Benlysta functions by binding to soluble B-lymphocyte stimulator (BLyS), a crucial protein for the survival of B cells. Unlike other therapies that directly target B cells, Benlysta does not bind to the them. Elevated levels of BLyS are associated with abnormal antibody production in SLE. By neutralizing BLyS, Benlysta reduces the survival of autoreactive B cells and limits their development into antibody-producing plasma cells. This targeted approach helps lower autoantibody levels and manage disease activity in lupus.5,6 

Administration and Dosage Overview: 

Intravenous (IV) Administration 

• For adults with SLE or lupus nephritis, and for pediatric patients with SLE, Benlysta is given intravenously at 10 mg/kg.  
• It is infused at 2-week intervals for the first three doses, then every 4 weeks.  
• Each dose is prepared by reconstituting and diluting the drug, followed by a 60-minute IV infusion.  

• Infusion rates may be slowed or paused if reactions occur, and therapy should be stopped immediately if a severe hypersensitivity reaction develops.7 

Subcutaneous (SC) Administration 

• For adults with SLE: Benlysta is given as 200 mg once weekly via subcutaneous injection in the abdomen or thigh. This dose is not weight-based. When switching from IV to SC, the first SC dose should be given 1–4 weeks after the last IV infusion. 
• For adults with lupus nephritis: the recommended regimen of Benlysta is 400 mg (two 200 mg injections) once weekly for the first four doses, followed by 200 mg once weekly thereafter.  

• Transition from IV to SC dosing can begin any time after the first two IV doses, with the first SC injection administered 1–2 weeks after the last IV infusion. 7 

Efficacy: Key Clinical Trials and Evidence 

Benlysta’s efficacy has been substantiated by landmark trials such as BLISS-52, BLISS-76, and BLISS-LN: 

• In the BLISS-LN (Lupus Nephritis) trial, 43% of patients achieved a primary renal response with Benlysta compared to 32% with placebo at two years.8 
• In the BLISS-76 (SLS) trial, adults with SLE who received Benlysta 10 mg/kg plus standard of care experienced significantly greater SLE Responder Index responses at week 52 (43.2%) compared to those with placebo (33.5%). In comparison, Benlysta at 1 mg/kg showed a 40.6% response.9 
• In BLISS-52, adults with SLE receiving Benlysta 1 mg/kg and 10 mg/kg showed higher SRI response rates (51% and 58%) compared to 44% with placebo at week 52. More patients experienced ≥4-point reductions in SELENA-SLEDAI scores (53% and 58%) and had no new severe flares (78% and 81%) compared to the placebo group.10 

Common Side Effects Reported in Patients 

The most frequent adverse reactions (≥3% of patients and higher than placebo) included nausea (15%), diarrhoea (12%), fever (10%), nasopharyngitis (9%), bronchitis (9%), insomnia (7%), extremity pain (6%), depression (5%), migraine (5%), pharyngitis (5%), cystitis (4%), leukopenia (4%), and viral gastroenteritis (3%). Serious infections were reported in 6–14% of patients, with a small percentage resulting in fatality, consistent with the known safety profile in lupus and lupus nephritis. 

Serious Warnings and Safety Considerations 

• Patients on Benlysta may develop serious or fatal infections, so risks and benefits should be carefully weighed, especially in those with chronic infections. Therapy should be paused if a new infection occurs, with close monitoring and follow-up. 
• Acute hypersensitivity reactions, including anaphylaxis, have been reported; patients should be monitored during and after infusions, and premedication may be considered. 
• Monitor for depression and suicidal thoughts, assessing psychiatric history before starting treatment and continuing vigilance throughout therapy. Patients and caregivers should promptly report any changes in mood. 
• Benlysta has not been studied in combination with other biologics, including B-cell targeted therapies, and is not recommended for use in combination with these treatments.7 

Benlysta vs. Other Lupus Treatments: How It Differs 

Benlysta offers a targeted approach that differs from traditional lupus therapies: 

• Fewer symptoms: Patients experienced improvements in muscles, joints, skin, mouth, and immune system activity. 
• Reduced steroid use: Benlysta helped lower steroid doses by ≥25%, with many patients achieving ≤7.5 mg/day during Weeks 40–52. 

• Fewer flares: Adding Benlysta to standard therapy reduced the risk of severe lupus flares, particularly in the first year of treatment. 

Ongoing Research and Future Applications 

Current research is exploring Benlysta’s use in: 

• Other B-cell–mediated autoimmune conditions, such as Sjögren’s syndrome and vasculitis.12 
• Exploring Benlysta’s combined use with other immune therapies, such as sequential treatment with rituximab. 13 
• It is also under investigation for its potential role in other autoimmune diseases with lupus, SLE, and lupus nephritis remaining its primary indications.13 

Conclusion 

Benlysta has shifted the treatment paradigm in lupus by targeting the BLyS pathway. Clinical evidence shows it reduces disease activity, lowers flare rates, and offers hope for patients with lupus nephritis. While vigilance for infections and hypersensitivity is critical, its overall safety profile is favourable compared with conventional immunosuppressants. With ongoing research, Benlysta’s role is likely to expand, potentially changing long-term outcomes for people living with lupus. 

Note: 

This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified healthcare provider with any questions regarding a medical condition or treatment. 

Disclaimer: 

Rx4U procures prescribed medicines directly from manufacturers or authorized distributors. It does not claim ownership of any trademarks and complies with the provisions of the Trademark Act, 1999, particularly Sections 30 and 30(1) concerning ‘Fair Use’. It solely facilitates access to new launches through named patient import. 

References 

• Charles A, Travers P, Walport M, Shlomchik MJ. Autoimmune responses are directed against self antigens [Internet]. Nih.gov. Garland Science; 2013. Available from: https://www.ncbi.nlm.nih.gov/books/NBK27155/ 
• Chapter 5 Systemic Lupus Erythematosus: Etiology, Pathogenesis, Clinical Manifestations, and Management. In: Handbook of Systemic Autoimmune Diseases [Internet]. Elsevier; 2007. p. 65–75. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1571507807060096 
• Rosenblum MD, Gratz IK, Paw JS, Abbas AK. Treating Human Autoimmunity: Current Practice and Future Prospects. Science Translational Medicine [Internet]. 2012 Mar 14;4(125):125sr1–1. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061980/ 
• GSK . FDA approves Benlysta (belimumab) Autoinjector for children with systemic lupus erythematosus | GSK US [Internet]. Gsk.com. 2024 [cited 2025 Sep 27]. Available from: https://us.gsk.com/en-us/media/press-releases/fda-approves-benlysta-belimumab-autoinjector-for-children-with-systemic-lupus-erythematosus/ 
• GSK. FDA approves GSK’s BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US | GSK US [Internet]. Gsk.com. 2020 [cited 2025 Sep 27]. Available from: https://us.gsk.com/en-us/media/press-releases/fda-approves-gsk-s-benlysta-as-the-first-medicine-for-adult-patients-with-active-lupus-nephritis-in-the-us/ 
• Singh JA, Shah NP, Mudano AS. Belimumab for systemic lupus erythematosus. Cochrane Database of Systematic Reviews. 2021 Feb 25;2021(2). 
• Rx4u. Buy Named Patient Medicines in India | Rx4u [Internet]. Rx4u. 2023 [cited 2025 Sep 27]. Available from: https://rx4u.in/immunology-treatments/benlysta-belimumab 
• Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. New England Journal of Medicine. 2020 Sep 17;383(12):1117–28. 
• Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis & Rheumatism. 2011 Nov 29;63(12):3918–30. 
• Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. The Lancet. 2011 Feb;377(9767):721–31. 
• Why BENLYSTA? | BENLYSTA (belimumab) [Internet]. www.benlysta.com. Available from: https://www.benlysta.com/about-benlysta-for-lupus/why-benlysta/ 
• Mariette X, Barone F, Baldini C, Bootsma H, Clark KL, De Vita S, et al. A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome. JCI insight [Internet]. 2022 Dec 8;7(23):e163030. Available from: https://pubmed.ncbi.nlm.nih.gov/36477362/ 
• Aranow C, Allaart CF, Amoura Z, Bruce IN, Cagnoli PC, Chatham WW, et al. Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study. Annals of the Rheumatic Diseases [Internet]. 2024 Aug 19 [cited 2024 Aug 28];ard-225686. Available from: https://ard.bmj.com/content/early/2024/08/19/ard-2024-225686